skip navigation

Skip Nav

HIV/AIDS News

New Guidance on Antiviral Product Development

Date: June 9, 2006
Source: Food and Drug Administration (FDA)
URL: http://aidsinfo.nih.gov/ContentFiles/FDA-6_8_06.pdf

New Guidance on Antiviral Product Development
FDA published, this week, a final Guidance for Industry on Antiviral Product Development--Conducting and Submitting Virology Studies to the Agency to assist sponsors in the development of antiviral drugs and biological products (i.e., therapeutic proteins and monoclonal antibodies) from the initial pre-IND through the new drug application (NDA) and postmarketing stages.
The guidance serves as a starting point for understanding what nonclinical and clinical virology data are important to support the submission of an Investigational New Drug Application (IND), New Drug Application (NDA), or Biologics License Application (BLA) for approval of an antiviral product. The guidance focuses on nonclinical and clinical virology study reports and makes recommendations for collecting and submitting resistance data to the Food and Drug Administration (FDA). Nonclinical and clinical virology study reports, based on collected data, are essential for FDA's review of antiviral drug investigational and marketing applications. Specific topics discussed in the guidance include:
Defining the mechanism of action Establishing specific antiviral activity of the investigational product Assessing the potential for antagonism of other antiviral products that might be used in combination with the investigational product Providing data on the development of viral resistance to the investigational product Providing data that identify cross-resistance to approved antiviral products having the same target The guidance document, and specific topic attachments are available on the FDA web site through the following links:
The Guidance The Guidance Attachment -Submitting HIV Resistance Data The Guidance Attachment- Submitting Influenza Resistance Data The Guidance Attachment- Submitting HBV Resistance Data The Guidance Attachment- Submitting HCV Resistance Data
Richard Klein Office of Special Health Issues Food and Drug Administration Kimberly Struble Division of Antiviral Drug Products Food and Drug Administration An archive of past list serve announcements is available on the FDA web site at http://www.fda.gov/oashi/aids/listserve/archive.html

Back to Top